Atara Biotherapeutics, Inc. (ATRA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Atara Biotherapeutics, Inc. (ATRA) is down 41.4% since the beginning of the year. At $11 per share, ATRA is trading 44.6% below its 52-week high of $19. Investors who bought $1,000 worth of ATRA shares 5 years ago would now be looking at an investment worth $27.

Atara Biotherapeutics, Inc. (ATRA) has returned -41.35% so far this year and 33.63% over the past 12 months. Over the last ten years, ATRA has returned -32.46% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Oct 16, 2014, ATRA's average daily return is +0.11%, while the average monthly return is +1.81%. At this rate, an investment would double in approximately 3.2 years.

Historically, 48% of months were positive and 52% were negative. The best month was May 2026 with a return of +120.3%, while the worst month was Jan 2026 at -71.3%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.

On a daily basis, ATRA closed higher 49% of trading days. The best single day was May 7, 2026 with a return of +92.8%, while the worst single day was Nov 9, 2023 at -80.2%.

Atara Biotherapeutics, Inc. has an annualized alpha of 5.53%, beta of 1.67, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since October 16, 2014.

• This stock participated in 148.52% of S&P 500 Index downside but only -3.44% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ATRA ranks 59 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Atara Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Atara Biotherapeutics, Inc. was 99.74%, occurring on Feb 20, 2026. The portfolio has not yet recovered.

The current Atara Biotherapeutics, Inc. drawdown is 99.34%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Atara Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Atara Biotherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.